Verrica Financial Statements From 2010 to 2025

VRCA Stock  USD 0.65  0.11  20.37%   
Verrica Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Verrica Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Verrica Pharmaceuticals financial statements helps investors assess Verrica Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Verrica Pharmaceuticals' valuation are summarized below:
Gross Profit
-7 M
Market Capitalization
59.7 M
Enterprise Value Revenue
6.5293
Revenue
7.6 M
Earnings Share
(1.48)
We have found one hundred twenty available fundamental trend indicators for Verrica Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Verrica Pharmaceuticals current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 19, 2025, Market Cap is expected to decline to about 34.5 M. In addition to that, Enterprise Value is expected to decline to about 34.1 M

Verrica Pharmaceuticals Total Revenue

5.59 Million

Check Verrica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verrica Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 9.9 M, Selling General Administrative of 61.8 M or Total Revenue of 5.6 M, as well as many indicators such as Price To Sales Ratio of 4.55, Dividend Yield of 0.0 or Days Sales Outstanding of 3.53. Verrica financial statements analysis is a perfect complement when working with Verrica Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Verrica Pharmaceuticals Correlation against competitors.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

Verrica Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets61.7 M54.1 M35.6 M
Slightly volatile
Other Current Liabilities14.2 M13.5 M3.5 M
Slightly volatile
Total Current Liabilities17.3 M29 M10.1 M
Slightly volatile
Accounts PayableM1.9 M633.1 K
Slightly volatile
Cash34.8 M46.3 M20.2 M
Slightly volatile
Cash And Short Term Investments54.6 M46.3 M31.5 M
Slightly volatile
Common Stock Shares Outstanding32.1 M51.8 M25.9 M
Slightly volatile
Liabilities And Stockholders Equity61.7 M54.1 M35.6 M
Slightly volatile
Capital Surpluse120.4 M234 M82.8 M
Slightly volatile
Other Current Assets3.7 M2.3 M2.2 M
Slightly volatile
Total Liabilities67.2 M64 M19.7 M
Slightly volatile
Short and Long Term Debt19.8 M14.9 M13 M
Slightly volatile
Preferred Stock Total Equity10.1 M17.8 M9.7 M
Slightly volatile
Total Current Assets57.7 M51.2 M33.3 M
Slightly volatile
Short Term Debt12.8 M13.6 M6.6 M
Slightly volatile
Common Stock9.4 KKK
Slightly volatile
Common Stock Total Equity3.3 K4.6 K2.7 K
Slightly volatile
Net Invested Capital44.2 M34.1 M34.1 M
Slightly volatile
Net Working Capital33.4 M22.2 M26.6 M
Slightly volatile
Property Plant And Equipment Net3.9 M2.6 M1.9 M
Slightly volatile
Other Assets0.860.9491.8 K
Pretty Stable
Property Plant And Equipment Gross4.4 M3.8 M2.1 M
Slightly volatile
Capital Stock4.6 KK3.6 K
Slightly volatile
Property Plant Equipment3.3 M4.5 M1.8 M
Slightly volatile
Short and Long Term Debt Total31.5 M45.9 M12.8 M
Slightly volatile
Capital Lease Obligations1.8 MM843.5 K
Slightly volatile
Non Current Liabilities Other1.2 M1.4 M552 K
Slightly volatile
Other Liabilities4.7 M5.3 M5.7 M
Slightly volatile
Current Deferred Revenue400 K450 K490.6 K
Slightly volatile
Long Term Debt29.1 M31 M36.1 M
Very volatile
Deferred Long Term Liabilities80 K90 K98.1 K
Slightly volatile

Verrica Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative61.8 M58.8 M15.6 M
Slightly volatile
Other Operating Expenses38.6 M73.5 M22.9 M
Slightly volatile
Research Development13.4 M11.8 M8.3 M
Slightly volatile
Total Operating Expenses38.2 M71.6 M22.7 M
Slightly volatile
Interest Income1.1 M1.4 M561.2 K
Slightly volatile
Depreciation And Amortization1.3 M1.3 M330.8 K
Slightly volatile
Reconciled Depreciation1.3 M1.3 M329.8 K
Slightly volatile

Verrica Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock23.3 M30.9 M14.5 M
Slightly volatile
Stock Based Compensation5.9 M7.2 M3.4 M
Slightly volatile
Begin Period Cash Flow73 M69.5 M15.2 M
Slightly volatile
Depreciation1.3 M1.3 M330.8 K
Slightly volatile
Capital Expenditures25.6 K27 K669.9 K
Slightly volatile
End Period Cash Flow25.1 M46.3 M14.6 M
Slightly volatile
Change To Netincome4.8 M7.8 M3.1 M
Slightly volatile
Change To Inventory389.6 K438.3 K477.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.554.793320.7655
Very volatile
Days Sales Outstanding3.533.714636.1037
Pretty Stable
Stock Based Compensation To Revenue0.960.94690.7073
Slightly volatile
Capex To Depreciation0.02020.021322.5087
Slightly volatile
EV To Sales4.54.741721.9679
Pretty Stable
Payables Turnover1.030.97730.3357
Slightly volatile
Sales General And Administrative To Revenue2.32.222.2096
Slightly volatile
Research And Ddevelopement To Revenue1.641.56491.5278
Slightly volatile
Capex To Revenue0.00340.00360.0621
Slightly volatile
Cash Per Share0.850.89421.5101
Pretty Stable
Days Payables Outstanding3553739.6 K
Slightly volatile
Income Quality0.890.79560.8298
Slightly volatile
Current Ratio1.681.76416.3788
Pretty Stable
Receivables Turnover10398.259727.7307
Slightly volatile
Capex Per Share5.0E-45.0E-40.0382
Slightly volatile
Revenue Per Share0.260.1460.3817
Slightly volatile
Interest Debt Per Share0.561.06840.3846
Slightly volatile
Debt To Assets0.890.84860.2387
Slightly volatile
Days Of Payables Outstanding3553739.6 K
Slightly volatile
Ebt Per Ebit0.841.16171.0158
Pretty Stable
Long Term Debt To Capitalization0.851.43870.742
Slightly volatile
Quick Ratio1.61.67926.3736
Pretty Stable
Net Income Per E B T0.861.021.014
Pretty Stable
Cash Ratio1.521.59694.9754
Very volatile
Days Of Sales Outstanding3.533.714636.1037
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.00041.0401
Very volatile
Fixed Asset Turnover1.612.93372.0258
Pretty Stable
Debt Ratio0.890.84860.2387
Slightly volatile
Price Sales Ratio4.554.793320.7655
Very volatile
Asset Turnover0.150.13980.147
Pretty Stable
Gross Profit Margin0.960.75510.9386
Slightly volatile

Verrica Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap34.5 M36.3 M271.2 M
Slightly volatile
Enterprise Value34.1 M35.9 M264 M
Slightly volatile

Verrica Fundamental Market Drivers

Cash And Short Term Investments46.3 M

Verrica Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Verrica Pharmaceuticals Financial Statements

Verrica Pharmaceuticals stakeholders use historical fundamental indicators, such as Verrica Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Verrica Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Verrica Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Verrica Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Verrica Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue450 K400 K
Total Revenue7.6 M5.6 M
Cost Of Revenue1.9 M1.9 M
Stock Based Compensation To Revenue 0.95  0.96 
Sales General And Administrative To Revenue 2.22  2.30 
Research And Ddevelopement To Revenue 1.56  1.64 
Revenue Per Share 0.15  0.26 
Ebit Per Revenue(8.71)(9.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:
Check out the analysis of Verrica Pharmaceuticals Correlation against competitors.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.48)
Revenue Per Share
0.146
Quarterly Revenue Growth
(0.83)
Return On Assets
(0.60)
Return On Equity
(15.47)
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.